$4.3m Non-Dilutive R&D Tax Rebate Received
Filed with ASX · · 2 pages · English
Summary by 6ix AI
EMvision Medical Devices Ltd. has announced the receipt of a cash refund under the Australian Government’s R&D Tax Incentive program, amounting to a significant sum for eligible activities conducted during the last financial year. This funding is intended to bolster the company's financial reserves, which already include a reported cash position and additional grant funding. The eligible activities for the refund included various clinical and engineering programs related to their medical devices.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- First Responder Successfully Trialled with MSU
- Notification regarding unquoted securities - EMV
- emu Regional Benefits Study Advancing
- emu Pivotal Trial Recruitment Surpasses 200 Patients
- Appendix 4E & Annual Report to 30 June 2026
Later from EMvision Medical Devices
- Date of AGM & Closing Date of Director Nominations
- Mayo Clinic emu Early Clinical Experience Presentation
- Notice of Annual General Meeting/Proxy Form
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices